Abstracts tagged "Biologic agents"

Abstract Number: 1646 • 2015 ACR/ARHP Annual Meeting
Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting? the ACT-Solo Study: An Analysis of Efficacy and Safety at 12 Months
Jacques Tebib¹, Isabelle Idier², Mathieu Coudert³, David Pau⁴, Jean-Francis Maillefert⁵ and Rene-Marc Flipo⁶, ¹Rheumatology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France, ²Chugai Pharma, La Defense, France, ³Statistics, Experis IT, Nanterre, France, ⁴Statistics, Roche, Boulogne-Billancourt, France, ⁵Rheumatology, University Hospital, Dijon, France, ⁶Rheumatology, University Hospital, Lille, France
Background/Purpose: Baseline factors influencing the use of tocilizumab (TCZ) in monotherapy (Mono) instead of combination with DMARDs (Combo) in real-life practice in RA patients (pts)…
Abstract Number: 2750 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Is Effective As 1st, 2nd and 3rd-Line Biologic DMARD in Patients with Rheumatoid Arthritis
Adrian Richter¹, Anja Strangfeld², Joern Kekow³, Arnold Bussmann⁴, Andreas Krause⁵, Carsten Stille⁶, Joachim Listing⁷ and Angela Zink⁸, ¹German Rheumatism Research Center, Berlin, Germany, ²Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³University of Magdeburg, Magdeburg, Germany, ⁴Rheumatologist, Geilenkirchen, Germany, ⁵Rheumatologist, Berlin, Germany, ⁶Rheumatologist, Hannover, Germany, ⁷Epidemiology, DRFZ, Berlin, Germany, ⁸Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany
Background/Purpose: In Germany, treatment with Tocilizumab (TCZ) is primarily used in rheumatoid arthritis patients with previous failures of biologic DMARDs. Effectiveness and adherence of TCZ…
Abstract Number: 2473 • 2014 ACR/ARHP Annual Meeting
Post-Marketing Surveillance of Efficacy and Safety of Tacrolimus Add-on Therapy in Japanese Rheumatoid Arthritis Patients Who Failed to Show an Adequate Response to Biological Dmards : Interim Analysis
Tsutomu Takeuchi¹ and Kota Ishida², ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ²Astellas Pharma Inc., Tokyo, Japan
Background/Purpose: Tacrolimus (TAC) is an immunosuppressive macrolide that blocks T cell activation by specifically inhibiting calcineurin, and it is widely administered following organ transplantation. TAC…
Abstract Number: 1736 • 2014 ACR/ARHP Annual Meeting
Immune Related Adverse Events Associated with Anti-CTLA-4 Antibodies: Systematic Review and Meta-Analysis
Anne Bertrand, Marie Kostine, Thomas Barnetche and Thierry Schaeverbeke, Rheumatology, Bordeaux University Hospital, Bordeaux, France
Background/Purpose CTLA-4 is a costimulatory molecule that downregulates T-cell activation and promotes an immunotolerance, well known by rheumatologist since the use of Abatacept. Targeting CTLA-4…
Abstract Number: 475 • 2014 ACR/ARHP Annual Meeting
Risk Analysis of a First Adverse Event and Recurrent Infections during Biological Therapy in Chronic Inflammatory Arthritis
G. Avila¹, Arnald Alonso¹, Andrea Pluma-Sanjurjo², Carolina Diaz², Roxana Juverdeanu², María América López-Lasanta¹ and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain
Background/Purpose Biological therapies (BT) have significantly improved the prognosis of chronic inflammatory arthritis (CIA) patients. Although they are characterized by a good safety profile, the…
Abstract Number: 2391 • 2014 ACR/ARHP Annual Meeting
Sustained Rheumatoid Arthritis Remission and Low Disease Activity: Analysis of 13 Years of Follow up in Clinical Practice
G. Avila¹, Arnald Alonso¹, María América López-Lasanta¹, Andrea Pluma-Sanjurjo², C. Diaz² and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain
Background/Purpose Biological therapies (BTs) have greatly improved the outcomes in RA patients and nowadays clinical remission (REM) and low disease activity (LDA) have become realistic…
Abstract Number: 1526 • 2014 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy after Multiple Courses of Rituximab in Rheumatoid Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibitors: 3-Year DataÂ
Catalin Codreanu¹, Ruxandra Ionescu², Ioan Ancuta³, Corina Mogosan⁴, Simona Rednic⁵, Paulina Ciurea⁶, Maria Suta⁷, Magda Parvu⁸, Andra Balanescu², Mihai Bojinca³, Dan Nemes⁹, Codrina Ancuta¹⁰ and Elena Rezus¹¹, ¹5 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ²Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ³Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, ⁴'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ⁵Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania, ⁶Clinical County Hospital,Craiova, Craiova, Romania, ⁷317 Tomis Str. , Bl. 4A, ap. 3, Constanta Municipal Hospital, Constanta, Romania, ⁸Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, ⁹Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ¹⁰G.T.Popa Center for Biomedical Research, Iasi, Romania, ¹¹Rheumatology, Recovering Clinical Hospital, Iasi, Romania
Background/Purpose Efficacy and safety of multiple courses of biologics used over extended periods of time in rheumatoid arthritis (RA) is still a medical debate. The…
Abstract Number: 470 • 2014 ACR/ARHP Annual Meeting
Safety Profile of Biologic Agents for Rheumatoid Arhtisitis Treatment after the Complication with Methotrexate-Related Lymphoproliferative Disorder
Shuntaro Saito¹, Yuko Kaneko¹, Katsuya Suzuki¹, Michihide Tokuhira² and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Hematology., Saitama Medical Center, Saitama Medical University., Saitama, Japan
Background/Purpose Lymphoproliferative disorder (LPD) is a rare complication in patients with rheumatoid arthritis(RA) treated with methotrexate(MTX). Although not a few patients experience exacerbation of RA…
Abstract Number: 2371 • 2014 ACR/ARHP Annual Meeting
Efficacy of First Line Biological Monotherapy in RA: Data from the Czech Registry Attra
Herman F. Mann^1,2, Sarka Forejtova³, Katerina Jarosova⁴, Ladislav Senolt⁵, Jakub Zavada⁶, Michal Uher⁷, Karel Hejduk⁷ and Karel Pavelka⁸, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ²1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁴Na Slupi 4, Institute of Rheumatology, Prague, Czech Republic, ⁵Na Slupi 4, Revmatologicky ustav, Prague, Czech Republic, ⁶Charles University, Prague, Czech Republic, ⁷Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: The biological disease-modifying anti-rheumatic drugs (bDMARDs) should be used for the treatment of rheumatoid arthritis (RA) in combination with conventional synthetic DMARDs (csDMARDs). However…
Abstract Number: 1540 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population
Brian Sauer¹, Chia-Chen Teng¹, Tao He¹, Jianwei Leng², Chao-Chin Lu¹, Neel Shah³, David J. Harrison⁴, Derek Tang⁴ and Grant W. Cannon⁵, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ³1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Biologics used for rheumatoid arthritis (RA) and ankylosing spondylitis (AS), including tumor necrosis factor blockers, are a key area of focus for Veterans Affairs…
Abstract Number: 280 • 2014 ACR/ARHP Annual Meeting
Biologic Treatment of Adult Patients with Juvenile Idiopathic Arthritis Followed in the National Registry
Katerina Jarosova¹, Karel Hejduk², Michal Uher² and Jiri Vencovsky, MD, DSc³, ¹clinical, Institution of Rheumatology, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ³Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic
Background/Purpose To analyze the efficacy and safety of biologic agents in adult patients with juvenile idiopathic arthritis (JIA).Methods ATTRA is the Czech national registry of…
Abstract Number: 2372 • 2014 ACR/ARHP Annual Meeting
Fatigue and Related Factors in Patients with Rheumatoid Arthritis Treated with Tocilizumab in Daily Clinical Setting
H Corominas¹, C Alegre de Miguel², M Rodríguez-Gómez³, C Marras Fernández-Cid⁴, F Maceiras Pan⁵ and ACT-AXIS Study Group, ¹Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²Rheumatology, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³Rheumatology, Complejo Hospitalario Cristal Piñor, Ourense, Spain, ⁴Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ⁵Rheumatology, Complejo Hospitalario Arquitecto Marcide-Profesor Novoa Santos, A Coruña, Spain
Background/Purpose: Fatigue in RA possibly resulting from alterations in the HPA axis like occurs with others RA symptoms as morning stiffness, and mood and sleep…
Abstract Number: 1357 • 2014 ACR/ARHP Annual Meeting
Improving Compliance for Tuberculosis Screening for Patients on Biologics in Rheumatology Clinics
Shraddha Jatwani¹, Rajani Rudrangi¹, Karan Jatwani², Vijaya Murthy¹, Rashmi Maganti¹, Rex McCallum¹ and Emilio Gonzalez¹, ¹Rheumatology, University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, Galveston, TX
Background/Purpose: Biologics are used commonly for patient with autoimmune diseases. These agents have ensured important efficacy advantages in the treatment of inflammatory rheumatic diseases. All…
Abstract Number: 293 • 2014 ACR/ARHP Annual Meeting
Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Janneke Anink¹, Femke Prince¹, Maryanne Dijkstra¹, Marieke H. Otten¹, Marinka Twilt², Rebecca ten Cate³, Simone Gorter⁴, Yvonne Koopman-Keemink⁵, Marion A.J. Van Rossum^6,7, Esther P.A. Hoppenreijs^8,9 and Lisette W.A. van Suijlekom-Smit¹, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Pediatric Rheumatology, Hagaziekenhuis Juliana Children's Hospital, The Hague, Netherlands, ⁶Pediatric Rheumatology, Reade, location Jan van Breemen, Amsterdam, Netherlands, ⁷Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ⁸Pediatric Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁹Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Juvenile idiopathic arthritis patients refractory to methotrexate are eligible for treatment with biologic agents. A longitudinal sub-analysis (n=53) of the Dutch Arthritis and Biologicals…
Abstract Number: 2341 • 2014 ACR/ARHP Annual Meeting
The Combination Therapy of Cell Cycle Regulation Therapy Combined and TNF Blockade Ameliorated the Established Arthritis
Tadashi Hosoya^1,2, Kimito Kawahata¹, Hideyuki Iwai¹ and Hitoshi Kohsaka^2,3, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Japan Science and Technology Agency–CREST Program, Tokyo, Japan, ³Department of Rheumatology, Graduate School of Medical and Dental Sciences,, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose The pathogenesis of rheumatoid arthritis (RA) is characterized by infiltration of inflammatory cells to the synovial tissues and their hyperplasia. Activated synovial fibroblasts become…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].